Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Published 2018 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Application of the CRISPR/Cas9 System to Drug Resistance in Breast Cancer
Authors
Keywords
-
Journal
Advanced Science
Volume 5, Issue 6, Pages 1700964
Publisher
Wiley
Online
2018-04-16
DOI
10.1002/advs.201700964
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Cancer-derived exosomes as a delivery platform of CRISPR/Cas9 confer cancer cell tropism-dependent targeting
- (2017) Seung Min Kim et al. JOURNAL OF CONTROLLED RELEASE
- Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes
- (2017) Brett T Staahl et al. NATURE BIOTECHNOLOGY
- Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
- (2017) Julia Joung et al. Nature Protocols
- Delivery technologies for genome editing
- (2017) Hao Yin et al. NATURE REVIEWS DRUG DISCOVERY
- CRISPR/Cas9: Transcending the Reality of Genome Editing
- (2017) Sergiu Chira et al. Molecular Therapy-Nucleic Acids
- Genome Editing for Cancer Therapy: Delivery of Cas9 Protein/sgRNA Plasmid via a Gold Nanocluster/Lipid Core-Shell Nanocarrier
- (2017) Peng Wang et al. Advanced Science
- Trastuzumab emtansine (T-DM1) plus docetaxel with or without pertuzumab in patients with HER2-positive locally advanced or metastatic breast cancer: results from a phase Ib/IIa study
- (2016) M. Martin et al. ANNALS OF ONCOLOGY
- An overview of the effective combination therapies for the treatment of breast cancer
- (2016) Cristina Núñez et al. BIOMATERIALS
- Neoadjuvant nab-paclitaxel in the treatment of breast cancer
- (2016) Naoto T. Ueno et al. BREAST CANCER RESEARCH AND TREATMENT
- Berberine reverses lapatinib resistance of HER2-positive breast cancer cells by increasing the level of ROS
- (2016) Ruohan Zhang et al. CANCER BIOLOGY & THERAPY
- TBCRC-010: Phase I/II Study of Dasatinib in Combination with Zoledronic Acid for the Treatment of Breast Cancer Bone Metastasis
- (2016) Z. Mitri et al. CLINICAL CANCER RESEARCH
- MicroRNA-34a and its target genes: Key factors in cancer multidrug resistance
- (2016) Morteza Ghandadi et al. CURRENT PHARMACEUTICAL DESIGN
- Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer
- (2016) Tommaso De Marchi et al. DRUG DISCOVERY TODAY
- CRISPR/Cas-mediated genome editing to treat EGFR-mutant lung cancer: a personalized molecular surgical therapy
- (2016) H. Tang et al. EMBO Molecular Medicine
- Emerging drugs targeting human epidermal growth factor receptor 2 (HER2) in the treatment of breast cancer
- (2016) Gil Awada et al. EXPERT OPINION ON EMERGING DRUGS
- Ixabepilone for the treatment of endometrial cancer
- (2016) Claudia Marchetti et al. EXPERT OPINION ON INVESTIGATIONAL DRUGS
- In Vivo Delivery Systems for Therapeutic Genome Editing
- (2016) Luyao Wang et al. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
- Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles
- (2016) Nazlı Erdoğar et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Genome Editing with CRISPR-Cas9: Can It Get Any Better?
- (2016) Maximilian Haeussler et al. Journal of Genetics and Genomics
- miR-200c: a versatile watchdog in cancer progression, EMT, and drug resistance
- (2016) Merve Mutlu et al. JOURNAL OF MOLECULAR MEDICINE-JMM
- A Genome-wide CRISPR Screen Identifies CDC25A as a Determinant of Sensitivity to ATR Inhibitors
- (2016) Sergio Ruiz et al. MOLECULAR CELL
- The CRISPR-associated DNA-cleaving enzyme Cpf1 also processes precursor CRISPR RNA
- (2016) Ines Fonfara et al. NATURE
- Chinese scientists to pioneer first human CRISPR trial
- (2016) David Cyranoski NATURE
- Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9
- (2016) John G Doench et al. NATURE BIOTECHNOLOGY
- Understanding the Genetic Mechanisms of Cancer Drug Resistance Using Genomic Approaches
- (2016) Xueda Hu et al. TRENDS IN GENETICS
- Combination of lapatinib with isothiocyanates overcomes drug resistance and inhibits migration of HER2 positive breast cancer cells
- (2016) Angelika Kaczyńska et al. Breast Cancer
- Long non-coding RNA regulation of epithelial–mesenchymal transition in cancer metastasis
- (2016) Q Xu et al. Cell Death & Disease
- Overcoming doxorubicin resistance of cancer cells by Cas9-mediated gene disruption
- (2016) Jong Seong Ha et al. Scientific Reports
- Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?
- (2016) Raffaella Palumbo et al. Therapeutic Advances in Medical Oncology
- Effective co-delivery of doxorubicin and dasatinib using a PEG-Fmoc nanocarrier for combination cancer chemotherapy
- (2015) Peng Zhang et al. BIOMATERIALS
- Engineering Complex Synthetic Transcriptional Programs with CRISPR RNA Scaffolds
- (2015) Jesse G. Zalatan et al. CELL
- Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas System
- (2015) Bernd Zetsche et al. CELL
- Upregulation of ER Signaling as an Adaptive Mechanism of Cell Survival in HER2-Positive Breast Tumors Treated with Anti-HER2 Therapy
- (2015) M. Giuliano et al. CLINICAL CANCER RESEARCH
- Molecular aspects of breast cancer resistance to drugs (Review)
- (2015) GLORIA M. CALAF et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Analysis of different HER-2 mutations in breast cancer progression and drug resistance
- (2015) Zijia Sun et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Cyclophosphamide-Mediated Tumor Priming for Enhanced Delivery and Antitumor Activity of HER2-Targeted Liposomal Doxorubicin (MM-302)
- (2015) E. Geretti et al. MOLECULAR CANCER THERAPEUTICS
- Engineered CRISPR-Cas9 nucleases with altered PAM specificities
- (2015) Benjamin P. Kleinstiver et al. NATURE
- Genome-scale transcriptional activation by an engineered CRISPR-Cas9 complex
- (2015) Silvana Konermann et al. NATURE
- Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition
- (2015) Benjamin P Kleinstiver et al. NATURE BIOTECHNOLOGY
- Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
- (2015) Junwei Shi et al. NATURE BIOTECHNOLOGY
- Multiplexable, locus-specific targeting of long RNAs with CRISPR-Display
- (2015) David M Shechner et al. NATURE METHODS
- CRISPR/Cas9-mediated gene editing in human tripronuclear zygotes
- (2015) Puping Liang et al. Protein & Cell
- Ecteinascidin 743 Interferes with the Activity of EWS-FLI1 in Ewing Sarcoma Cells
- (2015) Patrick J. Grohar et al. NEOPLASIA
- Multi-drug resistance in cancer chemotherapeutics: Mechanisms and lab approaches
- (2014) Qiong Wu et al. CANCER LETTERS
- Crystal Structure of Cas9 in Complex with Guide RNA and Target DNA
- (2014) Hiroshi Nishimasu et al. CELL
- Genome-Scale CRISPR-Mediated Control of Gene Repression and Activation
- (2014) Luke A. Gilbert et al. CELL
- Development and Applications of CRISPR-Cas9 for Genome Engineering
- (2014) Patrick D. Hsu et al. CELL
- ERK/MAPK regulates ERRγ expression, transcriptional activity and receptor-mediated tamoxifen resistance in ER+ breast cancer
- (2014) Mary M. Heckler et al. FEBS Journal
- Raloxifene Induces Autophagy-Dependent Cell Death in Breast Cancer Cells via the Activation of AMP-Activated Protein Kinase
- (2014) Dong Eun Kim et al. MOLECULES AND CELLS
- High-throughput screening of a CRISPR/Cas9 library for functional genomics in human cells
- (2014) Yuexin Zhou et al. NATURE
- Reversible and adaptive resistance to BRAF(V600E) inhibition in melanoma
- (2014) Chong Sun et al. NATURE
- In vivo interrogation of gene function in the mammalian brain using CRISPR-Cas9
- (2014) Lukasz Swiech et al. NATURE BIOTECHNOLOGY
- Genome editing with Cas9 in adult mice corrects a disease mutation and phenotype
- (2014) Hao Yin et al. NATURE BIOTECHNOLOGY
- Comprehensive analysis of the specificity of transcription activator-like effector nucleases
- (2014) Alexandre Juillerat et al. NUCLEIC ACIDS RESEARCH
- Targeting non-coding RNAs with the CRISPR/Cas9 system in human cell lines
- (2014) Tsui-Ting Ho et al. NUCLEIC ACIDS RESEARCH
- CCNA2 Is a Prognostic Biomarker for ER+ Breast Cancer and Tamoxifen Resistance
- (2014) Tian Gao et al. PLoS One
- MACROD2overexpression mediates estrogen independent growth and tamoxifen resistance in breast cancers
- (2014) Morassa Mohseni et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Structures of Cas9 Endonucleases Reveal RNA-Mediated Conformational Activation
- (2014) M. Jinek et al. SCIENCE
- Functional significance of long non-coding RNAs in breast cancer
- (2014) Rajeev Vikram et al. Breast Cancer
- Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research
- (2014) M. Hidalgo et al. Cancer Discovery
- HER2 confers drug resistance of human breast cancer cells through activation of NRF2 by direct interaction
- (2014) Hyo Jin Kang et al. Scientific Reports
- Novel drugs that target the estrogen-related receptor alpha: their therapeutic potential in breast cancer
- (2014) Felicity May Cancer Management and Research
- Dynamic Imaging of Genomic Loci in Living Human Cells by an Optimized CRISPR/Cas System
- (2013) Baohui Chen et al. CELL
- CRISPR-Mediated Modular RNA-Guided Regulation of Transcription in Eukaryotes
- (2013) Luke A. Gilbert et al. CELL
- Multiplexed activation of endogenous genes by CRISPR-on, an RNA-guided transcriptional activator system
- (2013) Albert W Cheng et al. CELL RESEARCH
- Toremifene for Breast Cancer: A Review of 20 Years of Data
- (2013) Charles L. Vogel et al. Clinical Breast Cancer
- Analysis of off-target effects of CRISPR/Cas-derived RNA-guided endonucleases and nickases
- (2013) S. W. Cho et al. GENOME RESEARCH
- Optical control of mammalian endogenous transcription and epigenetic states
- (2013) Silvana Konermann et al. NATURE
- DNA targeting specificity of RNA-guided Cas9 nucleases
- (2013) Patrick D Hsu et al. NATURE BIOTECHNOLOGY
- RNA-guided gene activation by CRISPR-Cas9–based transcription factors
- (2013) Pablo Perez-Pinera et al. NATURE METHODS
- CRISPR RNA–guided activation of endogenous human genes
- (2013) Morgan L Maeder et al. NATURE METHODS
- Orthogonal Cas9 proteins for RNA-guided gene regulation and editing
- (2013) Kevin M Esvelt et al. NATURE METHODS
- RNA-Guided Human Genome Engineering via Cas9
- (2013) P. Mali et al. SCIENCE
- Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
- (2013) Ophir Shalem et al. SCIENCE
- Genetic Screens in Human Cells Using the CRISPR-Cas9 System
- (2013) Tim Wang et al. SCIENCE
- Multiplex Genome Engineering Using CRISPR/Cas Systems
- (2013) L. Cong et al. SCIENCE
- Association between common risk factors and molecular subtypes in breast cancer patients
- (2012) Fatma P. Turkoz et al. BREAST
- New therapies in HER2-positive breast cancer: A major step towards a cure of the disease?
- (2012) Ahmad Awada et al. CANCER TREATMENT REVIEWS
- MED12 Controls the Response to Multiple Cancer Drugs through Regulation of TGF-β Receptor Signaling
- (2012) Sidong Huang et al. CELL
- Prevalence, Clinicopathologic Associations, and Molecular Spectrum of ERBB2 (HER2) Tyrosine Kinase Mutations in Lung Adenocarcinomas
- (2012) M. E. Arcila et al. CLINICAL CANCER RESEARCH
- Chemotherapy-Resistant Metastatic Breast Cancer
- (2012) Carrie Marquette et al. CURRENT TREATMENT OPTIONS IN ONCOLOGY
- Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems
- (2012) Oktay Tacar et al. JOURNAL OF PHARMACY AND PHARMACOLOGY
- Induction of estrogen receptor α-36 expression by bone morphogenetic protein 2 in breast cancer cell lines
- (2012) DINGDING WANG et al. Molecular Medicine Reports
- Two Hundred Years of Cancer Research
- (2012) Vincent T. DeVita et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Programmable Dual-RNA-Guided DNA Endonuclease in Adaptive Bacterial Immunity
- (2012) M. Jinek et al. SCIENCE
- Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
- (2012) Ron Bose et al. Cancer Discovery
- Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future?
- (2011) J. T. Ribeiro et al. ANNALS OF ONCOLOGY
- The turnover of estrogen receptor α by the selective estrogen receptor degrader (SERD) fulvestrant is a saturable process that is not required for antagonist efficacy
- (2011) Suzanne E. Wardell et al. BIOCHEMICAL PHARMACOLOGY
- Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda®
- (2011) Maria Ait-Tihyaty et al. BREAST CANCER RESEARCH AND TREATMENT
- New drugs for breast cancer subtypes: Targeting driver pathways to overcome resistance
- (2011) Giuseppe Curigliano CANCER TREATMENT REVIEWS
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- A public genome-scale lentiviral expression library of human ORFs
- (2011) Xiaoping Yang et al. NATURE METHODS
- Mastering RNAi in mice
- (2011) Louisa Flintoft NATURE REVIEWS GENETICS
- Evolution and classification of the CRISPR–Cas systems
- (2011) Kira S. Makarova et al. NATURE REVIEWS MICROBIOLOGY
- Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer
- (2011) Joyce O'Shaughnessy et al. NEW ENGLAND JOURNAL OF MEDICINE
- Eribulin Induces Irreversible Mitotic Blockade: Implications of Cell-Based Pharmacodynamics forIn vivoEfficacy under Intermittent Dosing Conditions
- (2010) Murray J. Towle et al. CANCER RESEARCH
- Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis
- (2010) Rajnish A. Gupta et al. NATURE
- Chromosome 9p21 SNPs Associated with Multiple Disease Phenotypes Correlate with ANRIL Expression
- (2010) Michael S. Cunnington et al. PLoS Genetics
- Poly(ADP-Ribose) Polymerase-1 Inhibitor Treatment Regresses Autochthonous Brca2/p53-Mutant Mammary Tumors In vivo and Delays Tumor Relapse in Combination with Carboplatin
- (2009) T. Hay et al. CANCER RESEARCH
- A Phase I Study with Neratinib (HKI-272), an Irreversible Pan ErbB Receptor Tyrosine Kinase Inhibitor, in Patients with Solid Tumors
- (2009) K.-K. Wong et al. CLINICAL CANCER RESEARCH
- Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application
- (2009) Aimee L. Jackson et al. NATURE REVIEWS DRUG DISCOVERY
- Long non-coding RNAs: insights into functions
- (2009) Tim R. Mercer et al. NATURE REVIEWS GENETICS
- Inhibition of Poly(ADP-Ribose) Polymerase in Tumors fromBRCAMutation Carriers
- (2009) Peter C. Fong et al. NEW ENGLAND JOURNAL OF MEDICINE
- Identification of CDK10 as an Important Determinant of Resistance to Endocrine Therapy for Breast Cancer
- (2008) Elizabeth Iorns et al. CANCER CELL
- New Therapeutic Options for Chemotherapy-Resistant Metastatic Breast Cancer
- (2008) Paolo Pronzato DRUGS
- Crosstalk between the Estrogen Receptor and the HER Tyrosine Kinase Receptor Family: Molecular Mechanism and Clinical Implications for Endocrine Therapy Resistance
- (2008) Grazia Arpino et al. ENDOCRINE REVIEWS
- Inhibition of centromere dynamics by eribulin (E7389) during mitotic metaphase
- (2008) T. Okouneva et al. MOLECULAR CANCER THERAPEUTICS
- Rapid “Open-Source” Engineering of Customized Zinc-Finger Nucleases for Highly Efficient Gene Modification
- (2008) Morgan L. Maeder et al. MOLECULAR CELL
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started